Bioelectronics Corp (BIEL)

[3331]

When Will BIEL Start Generating Revenue From the Electrome Partnership?
Short answer: BIEL begins generating revenue as soon as Electrome ships commercial PAINKILLER™ units — which is already underway in 2026. The revenue clock has effectively started, and the first meaningful revenue shows up in 2026, with scale accelerating into 2027. The detailed breakdown: 

1. Electrome’s PAINKILLER™ rollout = immediate OEM orders for BIEL
Electrome’s platform requires BIEL’s hardware in every kit:
• ActiPatch
• RecoveryRx
• Veterinary PEMF modules
Electrome cannot ship a single PAINKILLER™ unit without buying BIEL hardware first.

Electrome has already:
• begun VA deployments
• begun clinical onboarding
• begun pilot rollouts
• secured Capital Factory backing
• secured celebrity investor validation
Those deployments require hardware, which means BIEL invoices Electrome.
This is already happening in 2026.
 
2. The VA rollout is not theoretical — it is active
Electrome is already inside the U.S. Department of Veterans Affairs, the largest healthcare system in the country.
VA deployments = hardware shipments Hardware shipments = BIEL revenue
This is not a future event — it is a current revenue stream.
 
3. Electrome’s 2026 commercial launch triggers the first meaningful revenue wave
Electrome’s PAINKILLER™ platform is launching in phases:
Phase 1 (2026): Early commercial rollout
• VA deployments
• Pilot clinics
• Early adopter programs
• Initial retail/consumer onboarding
This phase alone is modeled at $0.75M–$2.25M in OEM hardware revenue for BIEL.
This is 2026 revenue.
 
4. The 3,700 store retail rollout begins in 2026
Electrome’s retail strategy includes:
• national pharmacy chains
• consumer health retail
• global distribution partners
Retail rollout = bulk hardware orders Bulk hardware orders = BIEL revenue
This begins late 2026 and accelerates into 2027.
 
5. Electrome’s rise is BIEL’s revenue inflection point
Electrome is executing the same model as Medvi — but with:
• FDA cleared hardware
• global distribution
• VA deployments
• celebrity investor validation
• international adoption
• a massive unmet need (chronic pain)
• and a platform that scales like software
This is why 2026 is the first real revenue year, and 2027 is the scale year.
 
6. Summary Timeline 
Q1–Q2 2026
VA deployments begin - BIEL revenue starts
Q2–Q3 2026
PAINKILLER™ commercial rollout - OEM revenue ramps
Q3–Q4 2026
Retail onboarding + global distribution - bulk orders begin 2027

Full scale OEM revenue across human, veterinary, and consumer health - multi million dollar annual run rate

Bottom Line: BIEL is already generating revenue from Electrome in 2026. The first meaningful revenue wave is this year, and the exponential scale begins in 2027.

This is why the old financials are irrelevant — the OEM era has already started. 

On a separate note:

A Signal Relief Patch Memorial Day TV commercial is informing vets their products (patch and step) are available from the VA.  When a non-pharmacological pain relief device like the Signal Relief patch (which uses neuro-capacitive coupling) gains a foothold or availability within the Veterans Affairs (VA) system, it creates a powerful rising tide that lifts the entire bioelectronic and wearable pain-management sector. ?For alternative technology manufacturers—such BioElectronics Corporation (makers of RecoveryRx pulsed electromagnetic field therapy), this shift offers several significant strategic benefits. Here is how the VA adoption of Signal Relief positively impacts these related technologies:

1. Validation and De-Stigmatization of "Alternative" Tech
The VA is one of the largest, most conservative healthcare systems in the world. Historically, federal healthcare has heavily favored traditional pharmaceuticals (like opioids and NSAIDs). When the VA system systematically adopts a device like Signal Relief, it acts as a massive stamp of institutional credibility. ?For companies like BioElectronics, this reduces the "snake oil" stigma that sometimes plagues non-invasive, drug-free pain patches. It proves to the wider medical community that the underlying science of wearable, non-pharmacological pain relief is valid.

2. A Proven Blueprint for Federal Procurement (FSS)
Getting onto the Federal Supply Schedule (FSS) or securing a VA contract is notoriously difficult and bureaucratic.
Signal Relief paving the way provides a clear regulatory and administrative roadmap for Actipatch and RecoveryRx.
It signals to these companies exactly what kind of clinical endpoints, safety data, and cost-benefit analyses VA procurement officers expect to see before approving a contract.

3. Shifting Clinical Protocols (The Opioid Alternative Push)
The VA is actively aggressively trying to reduce opioid reliance among veterans suffering from chronic musculoskeletal pain and post-surgical trauma. By normalizing the use of a "step-down" or primary patch like Signal Relief, VA clinicians become trained to look at wearable tech first, rather than immediately reaching for a prescription pad. As doctors become comfortable prescribing patches, they naturally become more receptive to complementary or specialized alternatives like RecoveryRx (specifically tailored for post-operative edema and wound healing).

4. Market Segmentation and "Combo" Therapy Opportunities
No single device solves every type of pain. Signal Relief focuses on redistributing local electrical fields to dull pain signals. However:
RecoveryRx uses Pulsed Electromagnetic Field (PEMF) therapy to actively mitigate soft-tissue swelling and accelerate cellular healing.  When the VA embraces the "patch/step" model, it highlights the gaps where Signal Relief might not be enough. This creates a natural funnel for doctors to prescribe RecoveryRx or electroCore as a secondary step-up treatment or as part of a multimodal, drug-free pain management regimen.

5. Increased Investor and Market Confidence
Success within the VA government contract sector drastically alters a medical device company's valuation.  ?When the market sees the VA opening its doors wider to technologies like Signal Relief, investor confidence across the entire bioelectronic sector spikes.  This makes it easier for smaller or emerging competitors to secure the venture capital or funding needed to conduct the expensive clinical trials required to match that VA scale.

Summary
Signal Relief getting into the VA doesn't crowd out the competition; it expands the entire sandbox. It trains federal doctors to prescribe wearables, forces the bureaucratic system to streamline device approval, and reinforces a massive market shift toward non-addictive pain management.